表紙:緑内障手術装置の世界市場(2023年):2022年~2028年の分析
市場調査レポート
商品コード
1312427

緑内障手術装置の世界市場(2023年):2022年~2028年の分析

2023 Glaucoma Surgical Device Market Report: Global Analysis for 2022 to 2028

出版日: | 発行: Market Scope, LLC | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
緑内障手術装置の世界市場(2023年):2022年~2028年の分析
出版日: 2023年07月31日
発行: Market Scope, LLC
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

過去数年間で、手術装置の選択肢は2倍以上に増加し、開発中の新しい装置の数から、今後5年間は急速な拡大が続くと予想されます。本レポートでは、このような競合各社の製品数の増加を分析し、タイプ別に予想される増加を図示しています。また、別セクションで持続性ドラッグデリバリー機器の進展も追跡しています。

サンプルビュー

当レポートでは、世界の緑内障手術装置市場について調査し、市場の概要とともに、今後5年間の市場予測、重要な将来動向、および市場に参入する企業の競合分析などを提供しています。

目次

  • 緑内障、緑内障人口、緑内障診断に関する背景情報。
  • 緑内障手術装置の現在の売上推定・売上予測(平均価格と総収入を含む)
  • 眼科医、眼科専門医、検眼医、一般医を含む機器購入予定者のプロファイル
  • メーカーに関する情報
  • 現在の償還率
目次

What's New:

The "2023 Glaucoma Surgical Device Market Report" analyzes a new trend in the treatment of glaucoma patients: earlier surgical intervention. The report projects market growth through 2028 and discusses the mix of combination cataract/glaucoma surgeries and standalone glaucoma procedures for eight regions of the world.

SAMPLE VIEW

Glaucoma laser technologies in development or early commercialization are expected to significantly increase overall laser penetration. The new report highlights some of these technologies, including the Belkin laser, ViaLase femtosecond laser, Elios excimer laser, and IOPtimate CO2 laser.

Surgical device options in the past few years have more than doubled, and rapid expansion is expected to continue over the next five years, based on the number of new devices in development. The report analyzes this growing number of products from each competitor and illustrates the expected increase by type. It also tracks the progress being made in sustained drug delivery devices in a separate section.

The "2023 Glaucoma Surgical Device Market Report" offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report covers prevalence for glaucoma worldwide and discusses the ophthalmologists who treat glaucoma. It also examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-four market competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report mainly focuses on the product categories of microstents, formerly referred to as minimally invasive glaucoma surgery (MIGS) devices; subconjunctival shunts; canal surgery devices; and tube shunts. It also examines lasers used in glaucoma procedures. Each segment provides an analysis of market competitors and five-year market forecasts for units and dollars.

Also included in the report:

  • Background information about glaucoma, glaucoma populations, and glaucoma diagnosis.
  • Estimates of current sales and sales forecasts for glaucoma devices, including average prices and total revenue.
  • Profiles of prospective device buyers, including ophthalmologists, ophthalmic specialists, optometrists, and general medical doctors.
  • Information about manufacturers.
  • Current reimbursement rates.

Author Profile:

William Freeman

Bill Freemanhas more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.

Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.

After leaving Mentor in 1999, Bill joined Market Scope in 2000 and now serves as executive vice president focusing on ophthalmic surgical cataract, retinal and glaucoma devices.